Device-related epistaxis risk: continuous-flow left ventricular assist device-supported patients
- PDF / 832,247 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 105 Downloads / 221 Views
RHINOLOGY
Device‑related epistaxis risk: continuous‑flow left ventricular assist device‑supported patients Alper Koycu1 · Omer Vural1 · Melike Bahcecitapar2 · Sabuhi Jafarov1 · Gulfem Beyazpinar1 · Deniz Sarp Beyazpinar3 Received: 6 April 2020 / Accepted: 10 June 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Background The aim of this study was to analyze the effect of device-dependent factors on epistaxis episodes comparing patients supported with a continuous-flow left ventricular assist device (CF-LVAD) to patients under the same antithrombotic therapy. Methods Patients who underwent CF-LVAD between 2012 and 2018 were reviewed retrospectively from the institutionally adopted electronic database. Patients who underwent mitral valve replacement (MVR) surgery receiving the same anticoagulant and antiaggregant therapy were included as a control group. Demographics, epistaxis episodes, and nonepistaxis bleeding between the two groups were compared. Results A total of 179 patients met the inclusion criteria (61 patients CF-LVAD group, 118 patients MVR group). The median (range) follow-up periods for the study (CF-LVAD) and control (MVR) groups were 370 (2819) and 545.70 (2356) days, respectively. There was a significant difference for frequency of bleeding episodes per month between CF-LVAD and MVR groups (p = 0.003
Data Loading...
